Cargando...
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
BACKGROUND: Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects are reported, with the major two being bleeding and ibrutinib-related atrial f...
Gardado en:
| Publicado en: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5996546/ https://ncbi.nlm.nih.gov/pubmed/29891001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0626-0 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|